Status:
COMPLETED
Benefit/Risk in Real Life of New Oral Anticoagulants and Vitamin K Antagonists in Patients Aged 80 Years and Over
Lead Sponsor:
Assistance Publique - Hôpitaux de Paris
Conditions:
Atrial Fibrillation
Eligibility:
All Genders
80+ years
Brief Summary
The aim of the study is to compare, in real life, the risk benefit (including both major bleeding and thrombotic events (TE) and death from any cause) associated with direct oral anticoagulants (DOA) ...
Detailed Description
* Context: Oral anticoagulation is recommended for prevention of stroke and thrombo-embolic events in people aged 80 years and over (octo+) suffering from non vavular atrial fibrillation (nv AF) and w...
Eligibility Criteria
Inclusion
- Aged 80 years and over
- Newly treated with oral anticoagulants (DOA or VKA) for nv AF (whatever its type) or for flutter
- Living in community or in nursing home
- And consulting a general practionner (GP) and/or a pharmacist participating to the Presage network
Exclusion
- Opposition of the patient to the collection of his personal data
- Follow-up deemed impossible
Key Trial Info
Start Date :
February 1 2015
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 1 2021
Estimated Enrollment :
159 Patients enrolled
Trial Details
Trial ID
NCT02286414
Start Date
February 1 2015
End Date
November 1 2021
Last Update
March 29 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Assistance Publique Hôpitaux de Paris
Paris, France, 75018